Cyclosporine Withdrawal from a Mycophenolate Mofetil–Containing Immunosuppressive Regimen
Open Access
- 1 July 2005
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 16 (7) , 2234-2240
Abstract
Maintenance immunosuppression with cyclosporine (CsA) is associated with nephrotoxicity, hyperlipidemia, and hypertension. This long-term study (core study + 4 yr of follow-up) investigated the long-term efficacy and safety of CsA withdrawal from a mycophenolate mofetil (MMF)-based regimen. Seventy-seven patients were maintained on CsA, MMF, and steroids (CsA-MMF group), and 74 were given a CsA-free regimen of MMF and steroids (MMF group). Serum creatinine and creatinine clearance were measured at 6-month intervals. Patient and graft survival, acute rejection episodes, malignancies, BP, and lipid profile were also recorded. At 5 yr, patient and graft survival was 93 and 88%, respectively, for the MMF group and 95 and 92%, respectively, for the CsA-MMF group. During follow-up, seven MMF patients experienced acute rejection episodes compared with one CsA-MMF patient (P = 0.0283). Nine grafts were lost to chronic rejection in the MMF group versus three in the CsA-MMF group. No demographic or immunologic characteristics were associated with acute or chronic rejection in the MMF group, but the doses of both MMF and steroids decreased significantly between 1 and 5 yr. The MMF group showed a trend toward improved creatinine clearance (67.4 versus 61.7 ml/min; P = 0.0500). Withdrawal of CsA from an MMF-containing immunosuppressive regimen resulted in an increased risk for acute rejection episodes and graft loss as a result of rejection throughout the 5-yr study period. The creatinine clearance–confirmed improvement in renal function observed at year 1 was maintained at 5 yr BP and cholesterol levels were well controlled in both groups.Keywords
This publication has 12 references indexed in Scilit:
- THE USE OF DACLIZUMAB AND MYCOPHENOLATE MOFETIL IN COMBINATION WITH CORTICOSTEROIDS AND CYCLOSPORINE (LOW DOSE VERSUS LOW DOSE FOLLOWED BY WITHDRAWAL) TO OPTIMIZE RENAL FUNCTION IN RECIPIENTS OF RENAL ALLOGRAFTSTransplantation, 2004
- Long-Term Benefits with Sirolimus-Based Therapy after Early Cyclosporine WithdrawalJournal of the American Society of Nephrology, 2004
- Chronic Renal Failure after Transplantation of a Nonrenal OrganNew England Journal of Medicine, 2003
- Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation1,2Transplantation, 2003
- Withdrawal of Cyclosporine or Prednisone Six Months after Kidney Transplantation in Patients on Triple Drug Therapy: A Randomized, Prospective, Multicenter StudyJournal of the American Society of Nephrology, 2002
- MYCOPHENOLATE MOFETIL IN RENAL ALLOGRAFT RECIPIENTSTransplantation, 1997
- CYCLOSPORINE (SANDIMMUN®) IN CADAVERIC RENAL TRANSPLANTATION TEN-YEAR FOLLOW-UP OF A MULTICENTER TRIALTransplantation, 1995
- Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantationThe Lancet, 1995
- The Adverse Impact of Cyclosporine on Serum Lipids in Renal Transplant RecipientsAmerican Journal of Kidney Diseases, 1991
- A Randomized Clinical Trial of Cyclosporine in Cadaveric Renal TransplantationNew England Journal of Medicine, 1986